Exelixis, Inc. (EXEL)
| Market Cap | 14.58B +35.1% |
| Revenue (ttm) | 2.44B +9.2% |
| Net Income | 860.62M +42.9% |
| EPS | 3.19 +53.4% |
| Shares Out | 247.78M |
| PE Ratio | 17.96 |
| Forward PE | 16.31 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 412,069 |
| Open | 57.65 |
| Previous Close | 57.22 |
| Day's Range | 57.33 - 59.09 |
| 52-Week Range | 33.76 - 59.72 |
| Beta | 0.42 |
| Analysts | Buy |
| Price Target | 53.69 (-8.75%) |
| Earnings Date | Nov 3, 2026 |
About EXEL
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF recep... [Read more]
Financial Performance
In 2025, Exelixis's revenue was $2.32 billion, an increase of 6.98% compared to the previous year's $2.17 billion. Earnings were $782.57 million, an increase of 50.13%.
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for EXEL stock is "Buy." The 12-month stock price target is $53.69, which is a decrease of -8.75% from the latest price.
News
Exelixis Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
China-originated innovation and policy risks are shaping strategy, with a focus on novel assets and targeted AI use. Cabozantinib's growth and exclusivity are defended, while zanzalintinib is poised for multi-indication expansion. Early pipeline decisions are data-driven.
Exelixis risk of rejection ‘low’ despite zanzalintinib delay, says William Blair
William Blair is “surprised” by the three-month delay of the PDUFA date for Exelixis (EXEL)’ new drug application for zanzalintinib in combination with atezolizumab, but believes the risk of rejection...
U.S. FDA extends review of Exelixis' cancer drug
The U.S. Food and Drug Administration has extended the review of Exelixis' experimental colorectal cancer drug combination by three months, the company said in a filing on Friday.
Exelixis says FDA extends review period for zanzalintinib NDA by three months
Exelixis (EXEL) announced that on September 10, the U.S. Food and Drug Administration notified Exelixis that it had extended the review period for Exelixis’ new drug application for zanzalintinib, in…
Exelixis Transcript: Citigroup’s Biopharma Back to School Summit 2026
Key priorities include expanding product franchises, especially CABOMETYX and zanzalintinib, across multiple indications and modalities. CABOMETYX shows durable growth in RCC and NETs, while zanzalintinib is positioned for major opportunities in CRC and RCC. AI-driven tools are enhancing commercial and R&D efficiency.
Adagene announces $2M milestone payment from Exelixis
Adagene (ADAG) announced the achievement of a milestone in its ongoing collaboration and license agreement with Exelixis (EXEL). The milestone achievement is related to a preclinical milestone event f...
Exelixis Transcript: Wells Fargo 21st Annual Healthcare Conference
CABO's growth is driven by RCC and NET, with exclusivity expected until 2031 and a $3B target. Zanza is poised for immediate CRC launch, supported by strong clinical data and expanded sales force. Strategic focus includes pipeline expansion, business development, and balanced capital allocation.
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in September: Wells Far...
Exelixis says appeals court affirmed ‘key portion’ of 2024 judgment
Exelixis (EXEL) announced that in the lawsuit Exelixis, Inc. vs. MSN Laboratories Private Limited et al., Civil Action No. 22-00228, the U.S. Court of Appeals for the Federal Circuit has…
Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civil Action No. 22-002...
Strong Sales, Earnings Send Exelixis Shares Higher
Exelixis, Inc. (EXEL) shares enjoying institutional support – up 43.5% in a year.
BMO starts Exelixis at Market Perform into patent cliff
BMO Capital initiated coverage of Exelixis (EXEL) with a Market Perform rating and $54 price target Exelixis is anchored by cabozantinib, a “durable, high margin, and cash generative” franchise, the…
Exelixis initiated with a Market Perform at BMO Capital
BMO Capital analyst David Lebowitz initiated coverage of Exelixis (EXEL) with a Market Perform rating and $54 price target BMO rolled out coverage on nine biotechnology companies, saying each might…
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $EXEL--EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law.
EXEL SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Exelixis
Exelixis lowered and narrowed its full-year 2026 revenue guidance, citing a slower-than-expected neuroendocrine-tumor ramp -- and shares declined. SueWallSt notifies investors of a pending investigati...
Leerink downgrades Exelixis to Market Perform following Q2 results
As previously reported, Leerink analyst Andrew Berens downgraded Exelixis (EXEL) to Market Perform from Outperform with a price target of $52, down from $55, following Q2 results that missed expectati...
Exelixis downgraded to Market Perform from Outperform at Leerink
Leerink downgraded Exelixis (EXEL) to Market Perform from Outperform with a $52 price target
Exelixis price target raised to $51 from $47 at Stifel
Stifel analyst Stephen Willey raised the firm’s price target on Exelixis (EXEL) to $51 from $47 and keeps a Hold rating on the shares.
Exelixis price target lowered to $52 from $56 at Truist
Truist analyst Gregory Renza lowered the firm’s price target on Exelixis (EXEL) to $52 from $56 and keeps a Hold rating on the shares. Exelixis reported a mixed Q2 with…
Exelixis reports Q2 non-GAAP EPS 91, consensus 86c
Reports Q2 revenue $628.7M, consensus $636.15M. “Exelixis (EXEL) continues to execute across the key pillars of our business, positioning the company to deliver on our strategic objectives for 2026 an...
Exelixis lowers FY26 revenue outlook to $2.5B-$2.55B from $2.525B-$2.625B
Consensus $2.6B.
Exelixis Earnings Call Transcript: Q2 2026
Q2 2026 revenues grew to $629M, with CABO franchise up 10% year-over-year and global revenues up 13%. Zanza's CRC NDA is under review, with multiple pivotal trials advancing and a robust pipeline supporting long-term growth. Guidance was lowered due to a slower NET ramp.
Exelixis Earnings release: Q2 2026
Exelixis released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Exelixis Quarterly report: Q2 2026
Exelixis has published its Q2 2026 quarterly earnings report on August 5, 2026.
Exelixis Slides: Q2 2026
Exelixis has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.